Assignee
MEDESIS PHARMA
FR·4 granted patents·4 pending applications·3 citations·filing 2014–2023
Top patents by PatentIndex Score
8 records- 0175US9452136B2Reverse micelle system comprising nucleic acids and use thereofMEDESIS PHARMA·Filed 2014·Granted Sep 27, 2016·3 cites·12 claims
- 0259US2024000832A1Treatment and prevention of injury due to radiation exposureMEDESIS PHARMA·Filed 2023·Application pending·0 cites
- 0358US2023129386A1Treatment of covid-19 with reverse micelle system comprising unmodified oligonucleotidesMEDESIS PHARMA·Filed 2022·Application pending·0 cites
- 0455US11793831B2Treatment and prevention of injury due to radiation exposureMEDESIS PHARMA·Filed 2019·Granted Oct 24, 2023·0 cites·17 claims
- 0554US2023144739A1Treatment of covid-19 with reverse micelle system comprising unmodified oligonucleotidesMEDESIS PHARMA·Filed 2021·Application pending·0 cites
- 0636US2019192420A1Use of a reverse-micellar system for delivering chelators of radionuclides and metalsMEDESIS PHARMA·Filed 2018·Application pending·0 cites
- 0735US11278568B2In situ preparation of cyano-bridged metal nanoparticles within a biocompatible reverse micellar systemMEDESIS PHARMA·Filed 2016·Granted Mar 22, 2022·0 cites·20 claims
- 0831US10172954B2Use of a reverse-micellar system for delivering chelators of radionuclides and metalsMEDESIS PHARMA·Filed 2015·Granted Jan 8, 2019·0 cites·5 claims
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →